- Home
- SRRK
as of 03-19-2026 2:21pm EST
$42.97
+$3.18
+7.99%
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.6B | IPO Year: | 2018 |
| Target Price: | $55.40 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | -33.20 |
| 52 Week Low/High: | $22.71 - $49.82 | Next Earning Date: | 03-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 449.79% |
| P/E Ratio: | -12.12 | Index: | N/A |
| Free Cash Flow: | -300637000.0 | FCF Growth: | N/A |
AI-Powered SRRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 72.78%
72.78%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Feb 23, 2026
Avg Cost/Share
$47.76
Shares
8,484
Total Value
$399,350.71
Owned After
98,445
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
7,989
Total Value
$371,713.79
Owned After
98,445
SEC Form 4
Parlavecchio Caryn
Sell
CHRO
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
9,035
Total Value
$420,382.29
Owned After
169,087
SEC Form 4
Marantz Jing L.
Sell
CHIEF MEDICAL OFFICER
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
4,157
Total Value
$193,417.73
Owned After
126,012
SEC Form 4
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Jan 22, 2026
Avg Cost/Share
$46.36
Shares
14,898
Total Value
$695,937.54
Owned After
98,445
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
8,406
Total Value
$373,879.55
Owned After
98,445
SEC Form 4
Parlavecchio Caryn
Sell
CHRO
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
6,600
Total Value
$293,552.82
Owned After
169,087
SEC Form 4
Marantz Jing L.
Sell
CHIEF MEDICAL OFFICER
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
5,798
Total Value
$257,881.70
Owned After
126,012
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sell | $47.76 | 8,484 | $399,350.71 | 98,445 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 | Sell | $46.53 | 7,989 | $371,713.79 | 98,445 | |
| Parlavecchio Caryn | SRRK | CHRO | Feb 17, 2026 | Sell | $46.53 | 9,035 | $420,382.29 | 169,087 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Feb 17, 2026 | Sell | $46.53 | 9,580 | $445,740.16 | 241,545 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sell | $46.53 | 4,157 | $193,417.73 | 126,012 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sell | $46.36 | 14,898 | $695,937.54 | 98,445 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 16, 2026 | Sell | $44.48 | 8,406 | $373,879.55 | 98,445 | |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16, 2026 | Sell | $44.48 | 6,600 | $293,552.82 | 169,087 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jan 16, 2026 | Sell | $44.48 | 8,016 | $356,533.24 | 241,545 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Jan 16, 2026 | Sell | $44.48 | 5,798 | $257,881.70 | 126,012 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 3, 2026 · 100% conf.
AI Prediction BUY
1D
+3.72%
$45.96
Act: +7.04%
5D
+8.72%
$48.17
Act: -0.02%
20D
+6.13%
$47.02
Price: $44.31 Prob +5D: 100% AUC: 1.000
0001104659-26-022547
Scholar Rock Holding Corporation_March 3, 2026 0001727196false00017271962026-03-032026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 3, 2026 Scholar Rock Holding Corporation (Exact Name of Registrant as Specified in Charter)
Delaware 001-38501 82-3750435
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
301 Binney Street, 3rd Floor, Cambridge, MA 02142 (Address of Principal Executive Offices) (Zip Code) (857) 259-3860 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share
SRRK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On March 3, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025 and to provide a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. Item 7.01. Regulation FD Disclosure. The Company will utilize slides during its conference call scheduled for 8:15 am ET on March 3, 2026 to announce its financial and operating results for the year ended December 31, 2025 and to provide a business update for the Company. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description
99.1 Press Release issued by the Company on March 3, 2026, furnished hereto.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Scholar Rock Holding Corporation
Date: March 3, 2026 By: /s/ Junlin Ho
Junlin Ho
General Counsel & Corporate Secretary
2025 Q4 Q4 2025 Earnings
8-K/A BUY Mar 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K/A BUYMar 3, 2026 · 100% conf.
AI Prediction BUY
1D
+3.72%
$45.96
Act: +7.04%
5D
+8.72%
$48.17
Act: -0.02%
20D
+6.13%
$47.02
Price: $44.31 Prob +5D: 100% AUC: 1.000
0001104659-26-022897
false 0001727196
0001727196
2026-03-03 2026-03-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): March 3, 2026
Scholar Rock Holding Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware 001-38501 82-3750435
(State or Other Jurisdiction of
Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
301 Binney Street, 3rd Floor, Cambridge, MA 02142
(Address of Principal Executive Offices) (Zip Code)
(857) 259-3860
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share
SRRK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
This Amendment No. 1 to the Current Report on Form 8-K amends Item 2.02 of the Current Report on Form 8-K filed on March 3, 2026 (the “Original Form 8-K”) solely to correct an error in the Earnings Release furnished as Exhibit 99.1 thereto (the “Exhibit”). As previously furnished, the Exhibit reflected a scrivener’s error relating to the net loss per common share for the quarter ended December 31, 2025 and the weighted average common shares outstanding, basic and diluted, for the quarter ended December 31, 2025, which has been corrected on Exhibit 99.1 to this Amendment No. 1. No other changes have been made to the Original Form 8-K.
Item 2.02. Results of Operations and Financial Condition.
On March 3, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025 and to provide a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
Item 7.01. Regulation FD Disclosure.
The Company will utilize slides during its conference call scheduled for 8:15 am ET on March 3, 2026 to announce its financial and operating results for the year ended December 31, 2025 and to provide a business update for the Company.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press Release issued by the Company on March 3, 2026, furnished hereto.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Scholar Rock Holding Corporation
Date: March 3, 2026 By: /s/ Junlin Ho
Junlin Ho
General Counsel & Corporate Secretary
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+3.72%
$45.96
Act: +7.04%
5D
+8.72%
$48.17
Act: -0.02%
20D
+6.13%
$47.02
Price: $44.31 Prob +5D: 100% AUC: 1.000
0001104659-26-002757
Scholar Rock Holding Corporation_January 12, 2026 0001727196false00017271962026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 12, 2026 Scholar Rock Holding Corporation (Exact Name of Registrant as Specified in Charter)
Delaware 001-38501 82-3750435
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
301 Binney Street, 3rd Floor, Cambridge, MA 02142 (Address of Principal Executive Offices) (Zip Code) (857) 259-3860 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share
SRRK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its preliminary cash balance as of December 31, 2025, a business update and further details on its 2026 strategic priorities. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company announced on January 12, 2026, that it estimates it had approximately $365 million (unaudited) of cash, cash equivalents and marketable securities as of December 31, 2025. This financial information is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the fourth quarter and fiscal year ended December 31, 2025. The audit of the Company’s consolidated financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information set forth above. The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 7.01. Regulation FD Disclosure. On January 12, 2026, the Company issued a press release announcing business updates and further details on its 2026 strategic priorities. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01. Other Events. The Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”) during the week of January 12, 2026. A copy of the slides to be presented by the Company at the Conference is filed as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meanin
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Compare SRRK vs Leading Stocks
See how SRRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.